Chapter President "Back of the Envelope" Pediatrician Poll

Your Practice's Supply of Nirsevimab

From Dr. Mary Beth Miotto, your MCAAP President:

Earlier this month, the CDC announced that with increasing supplies of Nirsevimab monoclonal antibody(brand name Beyfortus) available for use nationally, pediatricians and birthing hospitals could return to the original guidance on immunizing infants. "CDC advises healthcare providers to return to recommendations put forward by CDC and the Advisory Committee on Immunization Practices (ACIP) on use of nirsevimab in young children".

Infants and children recommended to receive nirsevimab should be immunized as quickly as possible. Healthcare providers should not reserve nirsevimab doses for infants born later in the season when RSV circulation and risk for exposure to RSV may be lower.

 https://emergency.cdc.gov/newsletters/coca/2024/010524a.html

What is your reaction to this announcement?

Have you received more Nirsevimab?"

Click here to complete the poll.

Please share the link with member and non-member pediatricians.